The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study
Keywords: Cost; Effectiveness; Bevacizumab; Colorectal; Cancer; MAX;